Future

The future of obesity treatment is oral, effective, and widely accessible.

The global obesity treatment market is projected to exceed $140 billion by 2035. This growth is driven by increasing recognition of obesity as a chronic disease, alongside growing demand for practical, affordable, and scalable therapeutic options.

We are at the forefront of a paradigm shift: oral small-molecule therapies are poised to replace injectable drugs as the standard of care. These treatments have the potential to significantly improve patient adherence, lower costs, and expand access to care across healthcare systems worldwide.

At Pharma Consult v. Niels Porksen, we see this shift as a strategic opportunity. Our focus is on validated, high-potential targets—such as GIP, Amylin, and GLP-1—and we use advanced AI-driven drug discovery to identify and refine next-generation compounds.

By combining scientific expertise with cutting-edge technology and a lean development model, we accelerate the path from idea to candidate. Our vision is to deliver therapies that not only match injectable treatments in efficacy but outperform them in convenience and scalability.

The future of obesity treatment is not just about managing symptoms—it’s about transforming lives. And with the right approach, we can make that future a reality.

Do you have any questions or would you like a non-binding offer?

Contact LeanBio today for competent sparring and advice

are you interested?

You want to hear more?

Let’s connect. Whether you’re looking to collaborate, invest, or explore how our approach to small molecule obesity treatment can create real-world impact, we’re ready to share our vision and progress with you.